A dynamic mathematical model for transdermal drug delivery is developed on the basis of the bi-layer skin/twocompartment body model. The effects of metabolism reaction in the viable skin, the drug binding and reservoir function in the stratum corneum, and the solubility and diffusivity of the drug in the skin on the permeation ratetime profile are extensively simulated. The effects of the pharmacokinetic parameters on the plasma concentration profile are also analyzed. The present model is useful not only for analyzing the rate of skin permeation but also for predicting the plasma concentration after transdermal drug delivery.
Introduction
For many years, drugs have been administered percutaneously to achieve localized pharmacological action. Recently, however, the skin has increasingly been used as a portal of entry for systemically active agents. In 1981 , ALZACorporation first introduced a product of transdermal therapeutic systems, Transderm-Scop®, for medication of motion sickness. In In spite of the great impact of transdermal drug delivery on pharmaceutical society, the mechanism of drug permeation across the skin is not clear due to the complicated structure of the skin. During the last decade, a number of researchers have extensively studied percutaneous absorption of drugs both experimentally and theoretically. They have made great efforts to understand the penetration of drugs through the skin. The permeation data, however, were frequently analyzed on simplistic assumptions such as a single layer skin, a constant diffusivity, a steady-state condition, a simplified boundary condition, a compartment model of skin, etc>l- 3, 6, 8, 9, [12] [13] [14] 18, 21, 23, 37, 43, 44) A mQre^^^_ proach is needed, at this stage of transdermal drug delivery studies, to elucidate the mechanism of percutaneous absorption.
The main resistance to drug transport across the JOURNAL OF CHEMICAL ENGINEERING OF JAPAN intact skin generally resides in drug diffusion through the stratum corneum, the outermost layer (dead keratinized) of the skin. In recent years, skin permeability of various drugs has been enhanced by physicaj 15.27,42) eiectrical,20) and/or biochemical (prodrug) approaches.22 44) As a result, drug permeation across the viable skin may play an important role in determining the overall rate of skin permeation. It is also well knownthat metabolism reaction takes place not in the stratum corneum but in the viable skin.25) Since the transdermal drug delivery system is usually applied to a specific site of the body for a long period of time, the metabolism reaction may be subject to the time-dependent activity of enzymes around the delivery system.
The present work is concerned with the dynamic mathematical modeling of transdermal drug delivery.
The skin permeation of drugs is simulated by a combined model of bi-layer skin diffusion and twocompartment body elimination. The effects of physical-chemical properties, such as the diffusivity, solubility, partition coefficient, enzyme activity, drug binding and stratum corneum reservoir function, on drug permeation across the skin are extensively investigated.
The effects of pharmacokinetic parameters, such as the elimination rate constant of the drug and the volume of distribution, on the plasma concentration-time profile are also discussed. A method for predicting the plasma concentration in vivo after transdermal drug delivery is proposed.
Model Formulation
A schematic diagram of the present diffusion/ compartment model is illustrated in Fig. 1 . The drug concentration on the surface of the stratum corneumis assumed to remain constant during the entire period of application of the transdermal drug delivery system. This is the usual case for skin-control transdermal drug delivery.28 31) The skin is histologically a three-layer membranewhich consists of the stratum corneum,viable epidermis and dermis. Schaefer et al. demonstrated a clear difference in drug distribution between the stratum corneumand the viable epidermis.25) They also found no discontinuity in the drug concentration profile between the viable epidermis and dermis.25) In addition, especially in vivo, the drug molecule permeated through the viable epidermis is absorbed rapidly through the microcirculation.45) In this study, therefore, the skin is assumed to be a bi-layer membrane which consists of the stratum corneum and the viable layer. The metabolites, B and C, generated in the viable skin, diffuse into the receptor compartment as well as into the stratum corneum based on Fick's equation (Fig. 1) . In general, the rate of back-diffusion into the stratum corneum is quite low due to the substantially small diffusivity in the stratum corneum. However, the back-diffusion into the stratum corneum maynot be neglected since the drug molecules in the stratum corneumplay an important role in the reservoir function of the stratum corneum. The back diffusion of the metabolites into the donor compartment may also be important for the in vitro skin permeation experiment using a reservoir-type donor compartment. The drugs through the viable skin are absorbed into the body compartments (blood circulation and tissue compartment). In this study, a twocompartment model with first-order elimination kinetics ( Fig. 1 ) is assumed to describe the drug concentrations in the plasma. The mass balance of drugs, A, B and C, over a differential volume element of the skin yields:
where the notations are summarized in the Nomenclature. Equations (1) to (3) are applied to the stratum corneum (0<x<h) without metabolism reaction and to the viable skin (h<x <H) without drug
At low concentration of drug A, Eqs. (1) to (3) reduce to:
Muchof the present study was carried out by using the simplified governing equations (la)-(3a). Recently, it was found that the bioconversion of estradiol diacetate followed first-order reaction kinetics. 35) The appropriate boundary conditions are:
i ) x=0 (donor-side surface):
where t2 is the duration of the transdermal drug delivery system.
If the metabolites, B and C, diffuse back into the donor compartment (device), the following boundary conditions may be used instead of Eqs. (6) and (7): 302 Cb=0 (sink condition) (8) Cc=0 (sink condition) (9) ii) x=h (stratum corneum/viable skin boundary): (10) Ci(h')=PiCi(h+) i=a9 b, c (ll) where P is the viable skin/stratum corneum partition coefficient. Kammerau et al. clearly demonstrated that the drug concentration changes discontinuously on the stratum corneum/viable skin boundary.16) On the contrary, the concentration changes continuously on the boundary between the epidermis and the dermis.24) The diffusivity in the viable epidermis is of the same order of magnitude as that in the dermis.26)
The initial conditions are:
The diffusivity of the drug across the skin is generally a function of the space coordinate (x), time (t) and concentration (C):
D=f(x, t, C) (13) In this study, the skin is assumed to be intact during the transdermal medication, and therefore the diffusivity is a function of the space coordinate only, as follows:
The diffusivity D1 across the stratum corneum is an effective diffusivity, 33) since the stratum corneum is a multicellular membrane which consists of flattened keratinized cells and lipid-rich intercellular ma-
The rate constants kx and k2 of the enzymatic reaction, A -> B -> C, are generally time-dependent because the enzyme in the viable skin may be degraded due to skin aging. This inactivation process of enzymes is important especially in in vitro skin permeation. In the present study, the kinetics of the enzymeinactivation is assumed to obey a decreasing exponential law: 5 35) A:i=ZI.exp(-^0 i= l, 2 (15) where Z is the intrinsic rate constant and A is the decay rate constant of enzymeactivity. tions into a set of ordinary differential equations.30) A numerical method (Runge-Kutta-Gill,4)) for ordinary differential equations is then used to solve the resulting equations to obtain numerical approximations to the original partial differential equations. Specifically, the formula of the second-order centered finite difference schemeis utilized for the present spatial discretization. The numberof spatial meshes specified for this study is 41 for each skin layer. The use of mesh points greater than 41 yields essentially identical results for the present calculation. To test the accuracy of numerical solution, it was compared with the analytical solution for a special case where no binding (p=q=0), first-order irreversible reaction (k2 =0) and unilayer membrane (Dx = D2 =constant, P= 1) were assumed. It was found that the viable skin is much greater than that in the stratum corneum (500-10,000 times,32<34)), the effect of back-diffusion of the metabolites on the overall permeation rate may be neglected under normal skin permeation conditions. However, the back-diffusion may affect appreciably the dynamics of transdermal drug delivery because the concentrations in the stratum corneumplay an important role in the reservoir function of the stratum corneum. In addition, if the resistance of the stratum corneumto permeation is minimized by an appropriate method such as the use of a skin enhancer, the effect of back-diffusion would becomemore significant. The effect of the rate constants k1 and k2 of the enzymatic reaction in the skin on the cumulative amount of drug permeated is shown in Fig. 3 . The rate constants were varied arbitrarily to demonstrate the effect of rate constants on permeation profile. The other parameters were the same as in Fig. 2 because kx is about 20 times k2.38) The effect of drug binding in the stratum corneum on the permeation profile is shown in Fig. 4 The steady-state rate of permeation of the drug is hardly influenced by the binding process. It is also found from Fig. 4 that the time-lag is significantly decreased by the first-order enzymatic reaction in the viable skin. This finding indicates that the time-lag method must carefully be applied to determine the diffusivity of drugs in the skin. If the membrane is a unilayer, the decrease in the time-lag caused by the enzymatic reaction can be explained analytically.36) Figure 5 shows the effects of partition coefficient P, defined as the ratio of the drug solubility in the stratum corneum to that in the viable skin, on the cumulative amount of the drug permeated. This calculation simulated the bioconversion of estradiol diacetate to estradiol in the hairless mouse skin. The steady-state rate of permeation decreases, while the time-lag increases as the partition coefficient increases. This is due to the decrease in drug solubility in the viable skin. Figure 6 shows the effects of the system-on (system applied) and system-off (system removed) of the transdermal drug delivery on the rate of drug permeation. In this simulation, a steady-state permeation was assumed at the system-off and system-on points.
Under the steady-state condition without enzymatic Fig. 4 reaction and binding, the initial concentration profiles for the system-off and system-on are given, respectively, as follows:
It is interesting to see that the permeation rate under the system-off condition changes more slowly than that under the system-on condition. This is due to the reservoir function of the stratum corneum. As can be expected from Eq. (20) but also by the solubility S or partition coefficient P.
In this simulation, neither enzymatic reaction nor drug binding was assumed. Therefore, the reservoir effect appeared in Fig. 6 is due to the slow diffusion of drug accumulated in the stratum corneum. If the binding takes place in the stratum corneum, a more significant reservoir effect may appear. The stratum corneumreservoir function was first demonstrated by Vicker,39) who found that the hydration or occlusion of the stratum corneum noticeably influenced the reservoir function. His result indicated that the amount of drug accumulated in the stratum corneum played an important role in the reservoir function. Figure 7 shows the effects of the enzymeactivity on the cumulative amount of drug permeated as a parameter of the enzyme inactivation constant (Eq. 15). In this calculation, the rate constant k1 was assumed to be much greater than k2, and therefore, drug A was completely bioconverted to drug B in the viable skin. The permeation rate of drug C gradually de- creased as the time increased. On the contrary, the permeation rate of drug B slowly increased with time. Since the enzyme activity depends largely on animal species, in vivo or in vitro conditions as well as the site of skin, the enzyme activity in the viable skin must be carefully taken into account to establish a reliable in vitro/in vivo correlation. The enzyme inactivation is usually important in in vitro skin permeation study. For transdermal prodrug delivery, however, the skin permeation may be affected significantly by the time-dependent enzyme activity under in vivo conditions, because the enzymes in the skin underneath the delivery system maynot be regenerated during a long period of the system application.
Plasma Concentration
The plasma concentration-time curve for transdermal drug delivery was calculated by solving the mass balance equations based on the two-compartment model (Eqs. 18 and 19) . The thickness of the total skin was assumed to be 200 micrometers, since the distance from the skin surface to the microcirculation is reported to be about 200 micrometers.17) The drug through the viable epidermis is uptaken almost entirely by the microcirculation system,45} although the resorption of drugs by this capillary system is not complete. The effect of the stratum corneumthickness on the plasma concentration-time profile is shown in Fig. 8 . This calculation simulated verapamil permeation across the humanskin. It can be seen that the plasma concentration for thin skins (5 and 10 micrometers thick) reaches a steady state before the system-off point (24 hours). However, the concentration for the thicker skins (15 and 20 micrometers thick) continuously increases for a certain period after the system-off point. This is due to the reservoir function of stratum corneumas mentioned earlier. Since the thickness of skin influences markedly not only the steady-state concentration but also the dynamics of the plasma concentration, the site of application of the skin-control transdermal drug delivery must be carefully determined.
The effect of the pharmacokinetic half-life t1/2(=0.693/KJ of the drug on the plasma concentration profile is simulated in Fig. 9 . The time to reach a steady-state concentration in the plasma is markedly influenced by the half-life of the drug. If the half-life of the drug is very short, such as that of nitroglycerine, the dynamics of the plasma concentration is determined almost entirely by the skin permeation characteristics.
On the contrary, if the drug has a very long half-life, such as that of clonidine, the body compartment determines the dynamics of the plasma concentration. Therefore, the optimum duration of the transdermal drug delivery system is a function of the physicochemical properties, such as diffusivity and solubility in the skin, as well as the pharmacokinetic parameters of the drug in the body compartment.
The dynamics of plasma concentration profile of nitroglycerin from a reservoir-type transdermal delivery system was simulated by the present model and compared with the clinical data reported by Good10) in Fig. 10 . The drug diffusivity and solubility in each skin layer were determined by bi-layer skin model29) with the time-lags and steady-state rates of permeation obtained in the in vitro permeation experiment using a hairless mouse skin. The pharmacokinetic properties of the two-compartment model ( Fig. 1) were calculated from the intravenous infusion data for monkeysreported by Wester et al^X)
The body weight was assumed to be 60kg. plasma concentration of nitroglycerin were obtained from the animal models. It is interesting to see from Fig. 10 that not only the steady-state concentration in the plasma but also the dynamic response of the concentration profiles agree fairly well with the clinical data except under the system-off condition after 24hours. This finding indicates that a hairless mouse and a monkey are good animal models for nitroglycerin to describe the skin permeation kinetics and to evaluate the pharmacokinetic parameters in human, respectively. It is also indicated that the present mathematical approach is useful for predicting the plasma concentration of nitroglycerin through transdermal administration. Under the system-off condition, the calculated profiles of plasma concentration show a typical reservoir effect of the stratum corneumbecause a considerable amount of nitroglycerin was accumulated in the stratum corneum under a steady-state condition. However, the experimental concentration decreases very rapidly after the removal of the transdermal delivery system (24hours). Colfer et al?) reported a similar finding for their nitroglycerin delivery system. This is probably due to the fact that part of the stratum corneum was stripped when the delivery system was removed. For the transdermal nitroglycerin delivery system, the stratum corneum contains about 95% of total drug in the skin under a steady-state condition.
In Fig. 10 , the plasma concentration profile, assuming that the stratum corneum is completely removed together with the delivery system, is also plotted as a dashed line. The experimental data are found to fall between the two extreme cases. In general, the reservoir-function of stratum corneum is significant for a highly lipophilic partly be stripped when the delivery system is re-(Eq. 15) [s l] moved, the effect of the reservoir function would be^e = elimination rate constant (Fig. l) [s"1] less Significant than expected from simulation. *å = inhibitionconstant of the second reaction
bmce each delivery system has its own charactens-, + , c +. J J k = rate constant ofenzymatic reaction tics with respect to adhesion to the skin surface, in viable skin [s"1] the system-off dynamics maybe affected by the design k12 = transfer rate constant between compartments of the delivery system as well as by the skin/drug (Fig-l 
